Summit Therapeutics is trading $13.35 (+4.87%) after announcing significant progression-free-survival improvement for ivonescimab plus chemotherapy versus placebo plus chemotherapy in previously treated EGFR-mutated advanced lung cancer.
- The announcement was made on August 25, 2026.
- The Phase III HARMONi trial covered 114 global sites and was published in The Lancet Oncology.
- The report does not provide volume or explicitly quantify the stock-price reaction.